Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead Extends Push Into Oncology With Agenus R&D Pact

Dec 21 2018

• By Sten Stovall

SyringeClinic — R&D Pact Provides Gilead Options To 3 Agenus immuno-oncology Assets • Source: Shutterstock

Related Content

Top 20 Pharma Ranks: As Some Move Up, Others Fall Down

Dec 13 2018

What's Gilead Getting From Kite For Nearly $12bn?

Aug 29 2017

Related Companies

Gilead Sciences, Inc.

Agenus Inc.

Kite Pharma, Inc.

Tango Therapeutics, Inc.

Additional Topics

Deals ImmunoOncology Commercial Companies Business Strategies Cancer BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.